TPWA
ALNY icon

Twin Peaks Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$9.26K – 309
2026
Q1 		$9.26K Buy
+28
New +$9.53K ﹤0.01% 1103
2025
Q3 		– Sell
-15
Closed -$6.25K – 245
2025
Q2 		$6.25K Buy
+15
New +$4.15K ﹤0.01% 1187

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's ALNY Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 28 shares — an estimated $9.26K sold.

Twin Peaks Wealth Advisors first reported a position in ALNY in Q2 2025 and held it in 2 quarters. The position peaked at $9.26K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 28 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.26K.
  • Twin Peaks Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Alnylam Pharmaceuticals position peaked at $9.26K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.